Viking Therapeutics Inc (NASDAQ: VKTX) is 372.33% higher on its value in year-to-date trading and has touched a low of $8.28 and a high of $99.41 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VKTX stock was last observed hovering at around $91.34 in the last trading session, with the day’s loss setting it -3.44%.
Currently trading at $87.90, the stock is 92.88% and 186.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.42 million and changing -3.77% at the moment leaves the stock 363.01% off its SMA200. VKTX registered 643.03% gain for a year compared to 6-month gain of 505.79%. The firm has a 200-day simple moving average (SMA200) of -$90.75.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 274.84% loss in the last 1 month and extending the period to 3 months gives it a 575.63%, and is 3.35% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.80% over the week and 12.36% over the month.
Viking Therapeutics Inc (VKTX) has around 27 employees, a market worth around $8.83B and $0.00M in sales. Distance from 52-week low is 961.59% and -11.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.59%).
Viking Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.28.The EPS is expected to shrink by -22.99% this year.
Viking Therapeutics Inc (VKTX) Top Institutional Holders
277 institutions hold shares in Viking Therapeutics Inc (VKTX), with institutional investors hold 78.58% of the company’s shares. The shares outstanding are 100.11M, and float is at 91.68M with Short Float at 13.11%. Institutions hold 74.31% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 14.98 million shares valued at $242.76 million. The investor’s holdings represent 14.97% of the VKTX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 6.89 million shares valued at $111.77 million to account for 6.89% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 5.11 million shares representing 5.11% and valued at over $82.87 million, while State Street Corporation holds 4.82% of the shares totaling 4.82 million with a market value of $78.12 million.
Viking Therapeutics Inc (VKTX) Insider Activity
A total of 0 insider transactions have happened at Viking Therapeutics Inc (VKTX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Lian Brian,the company’sPresident & CEO. SEC filings show that Lian Brian sold 45,000 shares of the company’s common stock on Feb 09 at a price of $29.90 per share for a total of $1.35 million. Following the sale, the insider now owns 2.14 million shares.
Viking Therapeutics Inc disclosed in a document filed with the SEC on Feb 08 that Lian Brian (President & CEO) sold a total of 269,079 shares of the company’s common stock. The trade occurred on Feb 08 and was made at $26.87 per share for $7.23 million. Following the transaction, the insider now directly holds 2.18 million shares of the VKTX stock.
Still, SEC filings show that on Feb 08, Rouan Sarah Kathryn (Director) disposed off 25,000 shares at an average price of $28.05 for $0.7 million. The insider now directly holds 0 shares of Viking Therapeutics Inc (VKTX).
Viking Therapeutics Inc (VKTX): Who are the competitors?
The company’s main competitors (and peers) include Societal CDMO Inc. (SCTL) that is trading -13.82% down over the past 12 months. Ultragenyx Pharmaceutical Inc. (RARE) that is 20.65% higher over the same period.
